Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

UK vs AAPG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–5 Matrix Metrics)

UK Overall Winner 6-Pillar Tally: UK 2 – 2 AAPG (2 Tie) Matrix Metrics: UK 5 – 5 AAPG

As of Nov 20, 2026, Ucommune International Ltd (UK) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). UK carries a Unified Composite Score of 41.3/100 (SELL) at $1.10 (N/M Forward P/E, -146.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin).

  • Growth vs. Quality Trade-Off: UK earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. AAPG 37.1/100 SELL) and 7.12β · 83% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although UK compares more favorably head-to-head, both UK (41.3/100 SELL) and AAPG (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: UK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UK vs AAPG
UK NASDAQ Head-to-Head Winner
Ucommune International Ltd Ordinary Shares
Services-Business Services, Nec
$1.10
-9.84% 1D
Market Cap $827,100
TTM Revenue $26M
Forward P/E N/M
Beta / 30D Vol 7.12β · 83% Vol
Unified Composite Score
41.3 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 65.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 23
RSI-14: 22.9 · SMA20: $1.56 · SMA50: $1.79
AAPG NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$11.97
-3.78% 1D
Market Cap $1.2B
TTM Revenue $643M
Forward P/E 8.4x
Beta / 30D Vol 1.36β · 64% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $14.33 · SMA50: $14.97

6-Pillar Scorecard Institutional Category Breakdown (UK 2 – 2 AAPG)

Columns: Metric · UK · AAPG
1. Valuation Multiples AAPG
Forward P/E N/M 8.4x
Trailing P/E N/M 8.4x
PEG Ratio N/M N/M
EV / Revenue N/M 1.8x
2. Growth & Scale AAPG
Revenue Growth (YoY) -45.4% +29.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $26M $643M
Market Cap $827,100 $1.2B
3. Profitability & Quality UK
Gross Margin -2.9% 93.9%
Operating Margin -146.0% -219.5%
Net Profit Margin -144.9% -228.5%
Return on Equity (ROE) -26.1% -236.6%
4. Balance Sheet & Cash Flow UK
Cash Generation (TTM) -$35M EBITDA -$1.34B EBITDA
Cash Flow Margin -133.6% EBITDA Mgn N/A
Net Cash / Leverage $42.15 Book/Sh · -26.1% ROE $0.89 Book/Sh · -236.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Real Estate Services Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UK (5) vs AAPG (5)
Institutional Metric UK AAPG Criterion Row Edge
Market Capitalization
Scale
$827,100 $1.2B Larger Scale AAPG
Trailing P/E Ratio
Valuation
N/M 8.4x Lower Multiple AAPG
Forward P/E Ratio
Valuation
N/M 8.4x Lower Multiple AAPG
Revenue Growth (YoY)
Growth
-45.4% +29.3% Higher Growth AAPG
Operating Margin (TTM)
Profitability
-146.0% -219.5% Higher Margin UK
Net Profit Margin
Profitability
-144.9% -228.5% Higher Margin UK
Return on Equity (ROE)
Capital Efficiency
-26.1% -236.6% Higher ROE UK
52-Week Range Position
Momentum
15% ($0–$6) 0% ($12–$34) Stronger Trend UK
Beta / 30D Volatility
Risk Regime
7.12β · 83% Vol 1.36β · 64% Vol Lower Realized Risk AAPG
Unified Institutional Score
Composite Signal
41.3 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite UK
Trailing 12M Revenue (USD)
Operating Scale
$26M $643M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-2.9% 93.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$35M EBITDA ($42.15 Book/Sh · -26.1% ROE) -$1.34B EBITDA ($0.89 Book/Sh · -236.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AAPG +19.46 pp
UK: -39.23% · AAPG: -19.77%
3M Horizon AAPG +19.0 pp
UK: -47.37% · AAPG: -28.37%
6M Horizon AAPG +26.78 pp
UK: -66.26% · AAPG: -39.48%
1Y Horizon UK +72.59 pp
UK: +10.0% · AAPG: -62.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UK vs AAPG. Trailing 12-month operating profitability (UK -146.0% vs AAPG -219.5%) and valuation multiples (UK N/M vs AAPG 8.4x Forward P/E) are benchmarked directly in Pillar 4 below.

UK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$26M
Gross Margin-2.9%
Op. Margin-146.0%
ROE / Fwd P/E-26.1% · N/M
AAPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$643M
Gross Margin93.9%
Op. Margin-219.5%
ROE / Fwd P/E-236.6% · 8.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AAPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UK Moat Profile Cyclical / Execution-Driven Positioning
Real Estate Services Operator
Competes within the Real Estate Services value chain with $827,100 market capitalization and -146.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AAPG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -219.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UK vs AAPG Key Questions & Quantitative Answers

As of Nov 20, 2026, Ucommune International Ltd (UK) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). UK carries a Unified Composite Score of 41.3/100 (SELL) at $1.10 (N/M Forward P/E, -146.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin). Growth vs. Quality Trade-Off: UK earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. AAPG 37.1/100 SELL) and 7.12β · 83% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although UK compares more favorably head-to-head, both UK (41.3/100 SELL) and AAPG (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: UK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AAPG leads the Growth & Scale pillar: UK posts -45.4% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (-2.9% gross margin, -146.0% operating margin), compared with AAPG at +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin). On trailing 12-month operating scale, UK generates $26M in USD-normalized revenue versus $643M for AAPG. In operating R&D and SG&A reinvestment, UK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AAPG.

AAPG screens cheaper on headline valuation multiples. UK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-133.6% EBITDA margin), whereas AAPG trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UK (-26.1% ROE) versus AAPG (-236.6% ROE) capital efficiency.

In options market volatility and institutional positioning, UK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (7.12β · 83% Vol realized risk). By comparison, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.